PF 04418948Potent and selective EP2 receptor antagonist CAS# 1078166-57-0 |
- AMG-208
Catalog No.:BCC1054
CAS No.:1002304-34-8
- SGX-523
Catalog No.:BCC1055
CAS No.:1022150-57-7
- PHA-665752
Catalog No.:BCC1181
CAS No.:477575-56-7
- SU11274
Catalog No.:BCC1243
CAS No.:658084-23-2
- Cabozantinib (XL184, BMS-907351)
Catalog No.:BCC1264
CAS No.:849217-68-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1078166-57-0 | SDF | Download SDF |
| PubChem ID | 25114442 | Appearance | Powder |
| Formula | C23H20FNO5 | M.Wt | 409.41 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (244.25 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 1-(4-fluorobenzoyl)-3-[(6-methoxynaphthalen-2-yl)oxymethyl]azetidine-3-carboxylic acid | ||
| SMILES | COC1=CC2=C(C=C1)C=C(C=C2)OCC3(CN(C3)C(=O)C4=CC=C(C=C4)F)C(=O)O | ||
| Standard InChIKey | LWJGMYMNSNVCEM-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C23H20FNO5/c1-29-19-8-4-17-11-20(9-5-16(17)10-19)30-14-23(22(27)28)12-25(13-23)21(26)15-2-6-18(24)7-3-15/h2-11H,12-14H2,1H3,(H,27,28) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent EP2 receptor antagonist (IC50 = 16 nM for human EP2 receptors). Displays over 2000-fold selectivity for EP2 receptors over EP1, EP3, EP4, DP1 amd CRTH2 receptors; exhibits <30% binding at a diverse panel of GPCRs and ion channels at a concentration of 10 μM. Inhibits PGE2-induced increases in intracellular cAMP; reverses PGE2-invoked relaxation of mouse trachea (IC50 = 2.7 nM). |
PF 04418948 Dilution Calculator
PF 04418948 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4425 mL | 12.2127 mL | 24.4254 mL | 48.8508 mL | 61.0635 mL |
| 5 mM | 0.4885 mL | 2.4425 mL | 4.8851 mL | 9.7702 mL | 12.2127 mL |
| 10 mM | 0.2443 mL | 1.2213 mL | 2.4425 mL | 4.8851 mL | 6.1063 mL |
| 50 mM | 0.0489 mL | 0.2443 mL | 0.4885 mL | 0.977 mL | 1.2213 mL |
| 100 mM | 0.0244 mL | 0.1221 mL | 0.2443 mL | 0.4885 mL | 0.6106 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
PF-04418948 is a novel, potent and selective prostaglandin EP2 receptor antagonist with IC50 of 16 nM, displays >2000-fold functional selectivity for the human EP2 receptor over antagonist activity against the human EP1, EP3, EP4, DP1 and CRTH2 receptors. IC50 value: 16 nM Target: EP2 in vitro: PF-04418948 inhibits prostaglandin E2 (PGE2)-induced increase in cAMP in cells expressing EP2 receptors with a functional KB value of 1.8 nM. In human myometrium, PF-04418948 produced a parallel, rightward shift of the butaprost-induced inhibition of the contractions induced by electrical field stimulation with an apparent KB of 5.4 nM. [1] in vivo: In dog bronchiole and mouse trachea, PF-04418948 produced parallel rightward shifts of the PGE2-induced relaxation curve with a KB of 2.5 nM and an apparent KB of 1.3 nM respectively. Reversal of the PGE2-induced relaxation in the mouse trachea by PF-04418948 produced an IC50 value of 2.7 nM. Given orally, PF-04418948 attenuated the butaprost-induced cutaneous blood flow response in rats. [1] PF-04418948 competitively inhibits relaxations of murine and guinea pig trachea induced by ONO-AE1-259 and PGE2 respectively.[2]
References:
[1]. af Forselles KJ, et al. In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP2 receptor antagonist. Br J Pharmacol. 2011 Dec;164(7):1847-1856.
[2]. Birrell MA, et al. Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2 receptor. Br J Pharmacol. 2013 Jan;168(1):129-138.
- 3,4-Dihydroxybenzenepropanoic acid
Catalog No.:BCN8500
CAS No.:1078-61-1
- Coccinic acid
Catalog No.:BCN5877
CAS No.:107783-45-9
- A 61603 hydrobromide
Catalog No.:BCC6912
CAS No.:107756-30-9
- Zafirlukast
Catalog No.:BCC4881
CAS No.:107753-78-6
- Methyl 7beta,15-dihydroxydehydroabietate
Catalog No.:BCN7270
CAS No.:107752-10-3
- Epleremone
Catalog No.:BCC3776
CAS No.:107724-20-9
- MDL 11,939
Catalog No.:BCC6822
CAS No.:107703-78-6
- beta-Lipoic acid
Catalog No.:BCC9198
CAS No.:6992-30-9
- Merucathine
Catalog No.:BCN1782
CAS No.:107673-74-5
- Bulleyaconitine A
Catalog No.:BCN1210
CAS No.:107668-79-1
- Merucathinone
Catalog No.:BCN1783
CAS No.:107638-80-2
- Erycibelline
Catalog No.:BCN1876
CAS No.:107633-95-4
- Exemestane
Catalog No.:BCC1061
CAS No.:107868-30-4
- Quinovin
Catalog No.:BCN5878
CAS No.:107870-05-3
- Dehydrodiconiferyl alcohol 4-O-beta-D-glucopyranoside
Catalog No.:BCN7707
CAS No.:107870-88-2
- Japonicones D
Catalog No.:BCN3614
CAS No.:1078711-42-8
- Isoeleutherin
Catalog No.:BCN8315
CAS No.:1078723-14-4
- Ganodermanondiol
Catalog No.:BCN5879
CAS No.:107900-76-5
- Sibiricose A5
Catalog No.:BCN2785
CAS No.:107912-97-0
- 9,9-Bis(4-amino-3-methylphenyl)fluorene
Catalog No.:BCC8794
CAS No.:107934-60-1
- Myricananin A
Catalog No.:BCN5880
CAS No.:1079941-35-7
- 2-(Dimethylamino)ethanol
Catalog No.:BCN1798
CAS No.:108-01-0
- Resorcinol
Catalog No.:BCN5881
CAS No.:108-46-3
- 6-Methyl-5,6-dihydropyran-2-one
Catalog No.:BCN3498
CAS No.:108-54-3
In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP(2) receptor antagonist.[Pubmed:21595651]
Br J Pharmacol. 2011 Dec;164(7):1847-56.
BACKGROUND AND PURPOSE: Studies of the role of the prostaglandin EP(2) receptor) have been limited by the availability of potent and selective antagonist tools. Here we describe the in vitro/in vivo pharmacological characterization of a novel EP(2) receptor antagonist, PF-04418948 (1-(4-fluorobenzoyl)-3-{[(6-methoxy-2-naphthyl)oxy]methyl} azetidine-3-carboxylic acid). EXPERIMENTAL APPROACH: Functional antagonist potency was assessed in cell-based systems expressing human EP(2) receptors and native tissue preparations from human, dog and mouse. The selectivity of PF-04418948 was assessed against related receptors and a panel of GPCRs, ion channels and enzymes. The ability of PF-04418948 to pharmacologically block EP(2) receptor function in vivo was tested in rats. KEY RESULTS: PF-04418948 inhibited prostaglandin E(2)(PGE(2))-induced increase in cAMP in cells expressing EP(2) receptors with a functional K(B) value of 1.8 nM. In human myometrium, PF-04418948 produced a parallel, rightward shift of the butaprost-induced inhibition of the contractions induced by electrical field stimulation with an apparent K(B) of 5.4 nM. In dog bronchiole and mouse trachea, PF-04418948 produced parallel rightward shifts of the PGE(2)-induced relaxation curve with a K(B) of 2.5 nM and an apparent K(B) of 1.3 nM respectively. Reversal of the PGE(2)-induced relaxation in the mouse trachea by PF-04418948 produced an IC(50) value of 2.7 nM. Given orally, PF-04418948 attenuated the butaprost-induced cutaneous blood flow response in rats. PF-04418948 was selective for EP(2) receptors over homologous and unrelated receptors, enzymes and channels. CONCLUSIONS AND IMPLICATIONS: PF-04418948 is an orally active, potent and selective surmountable EP(2) receptor antagonist that should aid further elaboration of EP(2) receptor function.
Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2 receptor.[Pubmed:22747912]
Br J Pharmacol. 2013 Jan;168(1):129-38.
BACKGROUND AND PURPOSE: Understanding the role of the EP(2) receptor has been hampered by the lack of a selective antagonist. Recently, a selective EP(2) receptor antagonist, PF-04418948, has been discovered. The aim of this study was to demonstrate the selectivity profile of PF-04418948 for the EP(2) receptor over other EP receptors using a range of isolated tissue systems. EXPERIMENTAL APPROACH: PF-04418948 was profiled on a range of isolated tissues to assess its EP receptor potency and selectivity: ONO-DI-004-induced contraction of guinea pig trachea (EP(1)); ONO-AE1-259 and PGE(2)- induced relaxation of mouse and guinea pig trachea (EP(2)); PGE(2)-induced depolarization of guinea pig isolated vagus (EP(3)); PGE(2)-induced relaxation of human and rat trachea (EP(4)). PF-04418948 was also profiled in functional murine TP, IP, DP and FP receptor assays. KEY RESULTS: In bioassay systems, where assessment of potency/selectivity is made against the 'native' receptor, PF-04418948 only acted as an antagonist of EP(2) receptor-mediated events. PF-04418948 competitively inhibited relaxations of murine and guinea pig trachea induced by ONO-AE1-259 and PGE(2) respectively. However, the affinity of PF-04418948 was not equal in the two preparations. CONCLUSIONS AND IMPLICATIONS: Using a wide range of bioassay systems, we have demonstrated that PF-04418948 is a selective EP(2)-receptor antagonist. Interestingly, an atypically low affinity was found on the guinea pig trachea, questioning its utility as an EP(2) receptor assay system. Nevertheless, this compound should be an invaluable tool for investigating the biological activity of PGE(2) and the role of EP(2) receptors in health and disease.
